Evidence map›Paper›PMID 34421583›Full record

ReviewFrontiers in pharmacology2021

Novel Antimicrobial Treatment Strategy Based on Drug Delivery Systems for Acute Otitis Media.

Masamitsu Kono, Nafisa K Umar, Saori Takeda, Makiko Ohtani, Daichi Murakami, Hideki Sakatani, Fumie Kaneko, Denisa Nanushaj, Muneki Hotomi

Open access · goldAbstract readReview
In one paragraph

Review in Frontiers in pharmacology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
2.1field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 14 citations in OpenAlex.

  1. Review
  2. Otitis Media Trial Publication After ClinicalTrials.gov Registration.Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery · 2025
    Observational
  3. Dynamic Nanopeptide Assemblies for Trans-Tympanic Drug Delivery.International journal of nanomedicine · 2025
    Article
  4. Article
  5. Review
  6. AMP-Coated TiOInternational journal of nanomedicine · 2024
    Article
  7. Article
  8. Frontiers in bioengineering and biotechnology · 2024
    Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Masamitsu KonoDepartment of Otorhinolaryngology-Head and Neck Surgery, Wakayama Medical University, Wakayama, Japan.
Nafisa K UmarDepartment of Otorhinolaryngology-Head and Neck Surgery, Wakayama Medical University, Wakayama, Japan.
Saori TakedaDepartment of Otorhinolaryngology-Head and Neck Surgery, Wakayama Medical University, Wakayama, Japan.
Makiko OhtaniDepartment of Otorhinolaryngology-Head and Neck Surgery, Wakayama Medical University, Wakayama, Japan.
Daichi MurakamiDepartment of Otorhinolaryngology-Head and Neck Surgery, Wakayama Medical University, Wakayama, Japan.
Hideki SakataniDepartment of Otorhinolaryngology-Head and Neck Surgery, Wakayama Medical University, Wakayama, Japan.
Fumie KanekoDepartment of Otorhinolaryngology-Head and Neck Surgery, Wakayama Medical University, Wakayama, Japan.
Denisa NanushajDepartment of Otorhinolaryngology-Head and Neck Surgery, Wakayama Medical University, Wakayama, Japan.
Muneki HotomiDepartment of Otorhinolaryngology-Head and Neck Surgery, Wakayama Medical University, Wakayama, Japan.
Wakayama Medical University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Despite tremendous success of pneumococcal conjugated vaccine and antimicrobial treatment by amoxicillin, acute otitis media (AOM) still remains as a great medical concern. Failure of antimicrobial treatment includes several factors. The middle ear cavity is surrounded by bone tissue, which makes it difficult to maintain sufficient concentration of antibiotics. Tympanic membrane of AOM patients thickens and actually becomes a barrier for topical therapy. This review discusses novel antimicrobial treatment strategies based on drug delivery systems (DDS) for AOM. To deliver drugs enough to kill the pathogenic bacteria without systemic side effects, the development of new antimicrobial treatment strategy applying innovative drug DDS has been expected. The sustained-release DDS can achieve sufficient time for antimicrobial concentrations to exceed minimum inhibitory concentration (MIC) for time-dependent antibiotics as well as enough maximum concentration for dose-dependent antibiotics to eradicate causative pathogens in the middle ear. The development of trans-tympanic membranes of DDS, such as hydrogels with chemical permeation enhancers (CPEs), is another attractive strategy. Phage is a promising strategy for developing DDS-based therapies. The DDS formulations enable antimicrobial treatment of AOM by a single dose and thus, an attractive future antimicrobial treatment for AOM.

Indexed as

acute otitis mediaantibioticsdrug delivery systemPK/PDsustained release

Identifiers

PMID34421583
PMCPMC8371970
OpenAlexW3192080171

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.